Zydus Cadila announces phase III trial of Desidustat

Zydus Cadila, an innovation-driven, global pharmaceutical company, announced the Phase III trials of Desidustat, an Inve...

April 17, 2019 | Wednesday | News
CStone Pharmaceuticals announces dosing in Ph III trial for treating adenocarcinoma

CStone Pharmaceuticals has announced that the first patient has been successfully enrolled and dosed in Phase III clinic...

April 16, 2019 | Tuesday | News
CStone receives IND approval in China for avapritinib study

CStone Pharmaceuticals has announced that the National Medical Products Administration (NMPA) recently approved the init...

April 15, 2019 | Monday | News
I-Mab Biopharma collaborates with Roche for combination therapy

I-Mab Biopharma (I-Mab), a clinical stage biopharmaceutical company exclusively focused on the development of potential ...

April 11, 2019 | Thursday | News
George Clinical establishes new presence in Singapore

George Clinical, a global scientifically backed clinical research organization, (CRO) has expanded its footprint in ...

April 10, 2019 | Wednesday | News
NIH begins first-in-human trial of a universal influenza vaccine candidate

The first clinical trial of an innovative universal influenza vaccine candidate is examining the vaccine’s safety ...

April 5, 2019 | Friday | News
Veeda Clinical Research Achieves ISO 27001:2013 Certification

India's leading independent CRO, Veeda Clinical Research Pvt. Ltd. has announced that Bureau Veritas has award...

April 3, 2019 | Wednesday | News
Veeda Clinical Research successfully completes third inspection by NPRA

Veeda Clinical Research Pvt. Ltd., a leading independent CRO has announced that its clinical (Shivalik, Ahmedabad) and B...

March 27, 2019 | Wednesday | News
Eisai starts Phase III clinical trial for Alzheimer's drug

Eisai Co., Ltd. has announced that a global Phase III clinical study (Clarity AD/Study 301) of BAN2401, an anti-amyloid ...

March 25, 2019 | Monday | News
WCG introduces a transformational solution for clinical research sites

WIRB-Copernicus Group has introduced WCG SiteReady, a first-of-its-kind solution aimed at increasing the efficiency and ...

March 20, 2019 | Wednesday | News
ImmunogenX initiates Ph2 trial for its lead therapeutic and diagnostic candidates Latiglutenase and CypCel

ImmunogenX has announced the initiation of a Phase 2 clinical trial (named Celiac Shield), sponsored by the Nationa...

March 18, 2019 | Monday | News
Bayer's Ph III clinical trial of Nifurtimox in pediatric patients with Chagas Disease meets primary endpoint

Bayer presented results from the CHICO part (CHagas disease In Children treated with NifurtimOx) of the phase III clinic...

March 15, 2019 | Friday | News
Alvotech enrolls first patient for Ph III study involving Biosimilar version of HUMIRA

Global biopharmaceutical company Alvotech has announced that it has enrolled the first patient in its Phase III clinical...

March 14, 2019 | Thursday | News
Kezar Life Sciences to test a new drug formulation of KZR-616

Kezar Life Sciences, a  South San Francisco-based clinical-stage biotechnology company discovering and developing n...

March 7, 2019 | Thursday | News
Dr Albers receives the distinguished Clinical Research Achievement Award for stroke research

iSchemaView, the worldwide leader in advanced imaging for stroke care and research, is proud to announce that iSchemaVie...

March 7, 2019 | Thursday | News
Exicure announces dosing of first patient in Ph1b/2 immuno-oncology trial

Exicure, a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drug...

February 25, 2019 | Monday | News
Foresee Pharma announces topline results of FP-001 LMIS in prostate cancer

Foresee Pharmaceuticals, a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange has announced tha...

February 22, 2019 | Friday | News
Enzychem Lifesciences completes Stage 1 patient enrollment in Ph2 CRIOM study

Enzychem Lifesciences, a global biopharmaceutical company headquartered in Seoul, Korea which is dedicated to developing...

February 22, 2019 | Friday | News